ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

ClinicalTrials.gov ID: NCT03346057

Public ClinicalTrials.gov record NCT03346057. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (ASA) Class 3 or 4 Subjects

Study identification

NCT ID
NCT03346057
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
344 participants

Conditions and interventions

Interventions

  • Neostigmine + Glycopyrrolate Drug
  • Rocuronium Drug
  • Sugammadex 16 mg/kg Drug
  • Sugammadex 2 mg/kg Drug
  • Sugammadex 4 mg/kg Drug
  • Vecuronium Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 19, 2017
Primary completion
Sep 3, 2019
Completion
Sep 3, 2019
Last update posted
Oct 7, 2020

2017 – 2019

United States locations

U.S. sites
20
U.S. states
16
U.S. cities
18
Facility City State ZIP Site status
University of Alabama - Birmingham ( Site 1046) Birmingham Alabama 35233
University Banner Medical Center ( Site 1019) Tucson Arizona 85719
Loma Linda University Medical Center ( Site 1029) Loma Linda California 92354
University of California Davis Medical Center ( Site 1001) Sacramento California 95817
Jackson Memorial Hospital ( Site 1007) Miami Florida 33136
University of Kansas Medical Center ( Site 1050) Kansas City Kansas 66160
Tulane University ( Site 1057) New Orleans Louisiana 70112
Ochsner Clinic Foundation ( Site 1005) New Orleans Louisiana 70121
Brigham & Women's Hospital ( Site 1039) Boston Massachusetts 02115
Beaumont Hospital, Royal Oak ( Site 1034) Royal Oak Michigan 48073
University Hospital- Columbia MO ( Site 1060) Columbia Missouri 65212
University of Missouri Health Care ( Site 1022) Columbia Missouri 65212
Jersey Shore University Medical Center ( Site 1058) Neptune City New Jersey 07753
Saint Peter's University Hospital [New Brunswick, NJ] ( Site 1017) New Brunswick New Jersey 08901
Mission Hospital - Memorial ( Site 1016) Asheville North Carolina 28801
Cleveland Clin Foundation ( Site 1032) Cleveland Ohio 44195
Temple University Hospital ( Site 1004) Philadelphia Pennsylvania 19140-5103
Vanderbilt University Medical Center ( Site 1033) Nashville Tennessee 37232
Hermann Drive Surgical Center ( Site 1021) Houston Texas 77004
Zablocki VA Medical Center ( Site 1011) Milwaukee Wisconsin 53295

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03346057, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 7, 2020 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03346057 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →